Paul Gray

Paul Gray

Auto-generated profile, based on publicly available information

Paul Gray

The University of Queensland, Australia; Queensland Health, Australia

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2011 in Pain
Verified
Journal Article
Closed access
PGPaul Gray
Paul Gray
JKJulie Kirby
Julie Kirby
Maree Therese SmithMaree Therese Smith
Maree Therese Smith
PCPeter J. Cabot
Peter J. Cabot
BWBronwyn Williams
Bronwyn Williams
TCTess Cramond
Tess Cramond
This randomised, double-blind, placebo-controlled trial assessed the efficacy and tolerability of pregabalin to alleviate the neuropathic component of moderate to severe burn pain. Patients aged 18 to 65 years admitted to a burns unit with a 5% or greater total body surface area burn injury were screened to participate in the trial. Using the Neuropathic Pain Scale (NPS), patients scoring 4 or higher on 'hot' pain or 'sharp' pain were invited to participate. Consenting patients were randomly assigned to receive pregabalin or placebo for 28 days with individual dose titration commencing at 75 mg twice daily to a maximum pregabalin dose of 300 mg twice daily. The primary outcome measure was the patients' daily response to the sharp and hot pain of the NPS. Secondary outcome measures included the remaining elements of the NPS, daily opioid requirement, length of hospital stay, pain at 6 months, and side effects of nausea, vomiting, drowsiness and giddiness. For patients administered pregabalin, the primary outcome measures hot (P = .01) and sharp (P = .04) pain were significantly reduced compared with those in patients administered placebo. Secondary outcome measures of itch, unpleasantness, surface pain, and procedural pain were significantly lower (P < .05) in the pregabalin group. Adverse effects were uncommon, with no difference between the treatment groups. There was no significant difference between the pregabalin and placebo treatment groups with respect to opioid consumption, duration of hospital stay, or pain at 6 months. Pregabalin was efficacious and well tolerated in patients after severe burn injury and whose pain was characterised by features of acute neuropathic pain. In this study, pregabalin was well tolerated and significantly reduced several elements of the neuropathic pain scale including hot pain, unpleasantness of the pain, surface pain, and itch, and also significantly reduced procedural pain.

1 April 2008 in Pain Medicine
Verified
Journal Article
Closed access
PDF file
PGPaul Gray
Paul Gray
BWBronwyn Williams
Bronwyn Williams
TCTess Cramond
Tess Cramond

11 December 2015 in Supportive Care in Cancer
Verified
Journal Article
Closed access
PDF file
PVPetra Vayne-Bossert
Petra Vayne-Bossert
BABanafsheh Afsharimani
Banafsheh Afsharimani
PGPhillip Good
Phillip Good
PGPaul Gray
Paul Gray
JHJanet Hardy
Janet Hardy

1 October 2008 in Current Opinion in Anaesthesiology
Verified
Journal Article
Closed access
PGPaul Gray
Paul Gray
Acute neuropathic pain (ANP) is a condition that is under-recognized, often difficult to treat and one that may progress to persistent pain and disability. This review examines the diagnosis and treatment in order to assist clinicians in providing better care to patients with this debilitating pain. The recent development of psychometric scales for the detection of neuropathic pain may assist in diagnosing ANP, though this is yet to be tested. Specific research into the treatment of ANP is sparse. However, several recent trials have shown that both tramadol and gabapentin are useful in mitigating neuropathic cancer pain. In addition, a recent trial suggests a combination of neural blockade with memantine may be useful in reducing ANP. The diagnosis of ANP is assisted by knowledge of the medical circumstances that have a higher risk of the condition developing, a detailed pain history with a directed examination and use of neuropathic pain scales. Although the data are lacking, agents that have demonstrated efficacy in persistent neuropathic pain states should be used in ANP. Refractory ANP could be treated with either intravenous lidocaine or calcitonin. Future research should be directed at validating a scale of neuropathic pain in ANP and conducting more therapeutic trials.

21 September 2023 in The Journal of Pain
Verified
Journal Article
Closed access
SFScott F. Farrell
Scott F. Farrell
NANigel R. Armfield
Nigel R. Armfield
PCPeter J. Cabot
Peter J. Cabot
RERachel A. Elphinston
Rachel A. Elphinston
PGPaul Gray
Paul Gray
MSMichele Sterling
Michele Sterling

1 April 2015 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
Samantha HollingworthSamantha Hollingworth
Samantha Hollingworth
PGPaul D. Gray
Paul D. Gray
WHWayne D. Hall
Wayne D. Hall
LKLeisa King
Leisa King